Consult a fertility specialist or clinical researcher prior to attempting BPC-157
#RegulatoryAffairs #FDA #PharmaRegulatory #OTC #DrugApproval To view or add a comment, sign in The FDAs Pharmacy Compounding Advisory Committee has just voted (July 2324, 2026) in favor of adding 6 of 7 peptides to the 503A bulk substances list
According to ProHealth's published quality disclosures, each batch of BPC-157 products undergoes independent third-party testing three times - covering identity, purity, and potency, as well as contaminants including heavy metals, microbial pathogens, residual solvents, and LPS (lipopolysaccharide) contamination
Book Your Drip Fill out the quick form or call us
In late 2023, the FDA added more than a dozen peptides including both BPC-157 and thymosin alpha 1 to its list of substances that should not be compounded because the agency has identified potential significant safety risks. For BPC-157, the agency warned that the peptide could trigger an immune response